Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

Programmed death-ligand 1 (PD-L1) expression on tumor cells (TCs) by immunohistochemistry is rapidly gaining importance as a diagnostic for the selection or stratification of patients with non-small cell lung cancer (NSCLC) most likely to respond to single-agent checkpoint inhibitors. However, at le...

詳細記述

保存先:
書誌詳細
出版年:Proc Natl Acad Sci U S A
主要な著者: Kowanetz, Marcin, Zou, Wei, Gettinger, Scott N., Koeppen, Hartmut, Kockx, Mark, Schmid, Peter, Kadel, Edward E., Wistuba, Ignacio, Chaft, Jamie, Rizvi, Naiyer A., Spigel, David R., Spira, Alexander, Hirsch, Fred R., Cohen, Victor, Smith, Dustin, Boyd, Zach, Miley, Natasha, Flynn, Susan, Leveque, Vincent, Shames, David S., Ballinger, Marcus, Mocci, Simonetta, Shankar, Geetha, Funke, Roel, Hampton, Garret, Sandler, Alan, Amler, Lukas, Mellman, Ira, Chen, Daniel S., Hegde, Priti S.
フォーマット: Artigo
言語:Inglês
出版事項: National Academy of Sciences 2018
主題:
PNAS Plus
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6205493/
https://ncbi.nlm.nih.gov/pubmed/30297397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1802166115
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料